196
Participants
Start Date
June 26, 2018
Primary Completion Date
April 5, 2019
Study Completion Date
April 5, 2019
JNJ-64565111 Dose Level 1
Participants will receive JNJ-64565111 Dose Level 1 SC once-weekly until Week 12.
JNJ-64565111 Dose Level 2
Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 12.
JNJ-64565111 Dose Level 3
Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 12.
Placebo
Participants will receive matching placebo to JNJ-64565111 SC once-weekly until Week 12.
Heritage Valley Medical Group, Beaver
Clinical Research Associates of Central PA, LLC, Altoona
M.D. Medical Research, Oxon Hill
Dominion Medical Associates, Inc., Richmond
National Clinical Research, Richmond
Spectrum Medical, Inc, Danville
CNS HealthCare, Orlando
Translational Research Institute for Metabolism and Diabetes, Orlando
Premeir Clinical Research Institute, Miami
International Research Associates, LLC, Miami
Central Research Associates, Inc., Birmingham
Clinical Research Associates Inc, Nashville
Prestige Clinical Research, Franklin
Albert J. Weisbrot and Associates, Mason
Buynak Clinical Research, Valparaiso
AAMRC, Flint
Cotton-O'Neil Clinical Research Center, Topeka
Dallas Diabetes & Endocrine Center at Medical City, Dallas
Baylor Endocrine Center, Dallas
Permian Research Foundation, Odessa
Alas Science Clinical Research, Henderson
National Research Institute, Los Angeles
Rancho Cucamonga Clinical Trials, Rancho Cucamonga
Encompass Clinical Research, Spring Valley
Diablo Clinical Research, Inc., Walnut Creek
Sierra Clinical Research, Roseville
Clinical Research Institute of Southern Oregon, P.C., Medford
Janssen Research & Development, LLC
INDUSTRY